LB54640 has shown targeted effect on MC4 receptor without hyperpigmentation Rhythm to advance LB54640 in two Phase 2 clinical trials BOSTON, Jan. 04, 2024 Rhythm Pharmaceuticals,.
MaxCyte Inc (NASDAQ:MXCT), a global cell-based therapies and life sciences company, has recently witnessed a significant insider sell by its President and CEO, Douglas Doerfler.
Oligonucleotide Synthesis, Modification, and Purification openpr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from openpr.com Daily Mail and Mail on Sunday newspapers.
ST. LOUIS, October 05, 2023 Geneoscopy will showcase its noninvasive RNA-based technology platform designed to improve diagnostic tools for gastrointestinal health.
Olivier Loeillot President and Chief Commercial Officer WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed 20+ year industry veteran Olivier Loeillot to the newly created position of President and Chief Commercial Officer (CCO), effective immediately. Mr. Loeillot served a combined 12 years with Cytiva (a Danaher company) and GE Healthcare Life Sciences